This clinical trial is focused on studying the effects of a medication called Guselkumab in individuals with moderately to severely active Crohn’s disease. Crohn’s disease is a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study aims to evaluate how effective and safe Guselkumab is for treating this condition. Guselkumab is administered as a solution for injection, and participants may also receive a placebo or another medication called Ustekinumab for comparison.

The trial is designed to be conducted in two phases. In the first phase, the focus is on assessing the clinical efficacy, which means how well the medication works in reducing the symptoms of Crohn’s disease. The second phase will look at both clinical and endoscopic efficacy, which involves using a camera to examine the inside of the digestive tract to see how the medication affects the inflammation. Participants will receive the treatment over a period of time, and their progress will be monitored to gather information on the medication’s safety and effectiveness.

Throughout the study, participants will receive injections of Guselkumab or Ustekinumab, or a placebo, and their health will be closely monitored by healthcare professionals. The study will help determine if Guselkumab can be a beneficial treatment option for people with Crohn’s disease, providing valuable insights into managing this challenging condition. The trial is expected to continue until 2027, allowing researchers to collect comprehensive data on the long-term effects of the treatment.